Arcturus Therapeutics Price To Book vs. Return On Asset

ARCT Stock  USD 16.91  0.16  0.94%   
Based on Arcturus Therapeutics' profitability indicators, Arcturus Therapeutics Holdings may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in December. Profitability indicators assess Arcturus Therapeutics' ability to earn profits and add value for shareholders. Price To Sales Ratio is likely to drop to 5.06 in 2024. Days Sales Outstanding is likely to drop to 44.44 in 2024. At this time, Arcturus Therapeutics' Net Income Per E B T is comparatively stable compared to the past year.
For Arcturus Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Arcturus Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Arcturus Therapeutics Holdings utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Arcturus Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Arcturus Therapeutics Holdings over time as well as its relative position and ranking within its peers.
  

Arcturus Therapeutics' Revenue Breakdown by Earning Segment

Check out Trending Equities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Arcturus Therapeutics. If investors know Arcturus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Arcturus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.33)
Revenue Per Share
5.955
Quarterly Revenue Growth
(0.08)
Return On Assets
(0.12)
Return On Equity
(0.23)
The market value of Arcturus Therapeutics is measured differently than its book value, which is the value of Arcturus that is recorded on the company's balance sheet. Investors also form their own opinion of Arcturus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Arcturus Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Arcturus Therapeutics' market value can be influenced by many factors that don't directly affect Arcturus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Arcturus Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Arcturus Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Arcturus Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Arcturus Therapeutics Return On Asset vs. Price To Book Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Arcturus Therapeutics's current stock value. Our valuation model uses many indicators to compare Arcturus Therapeutics value to that of its competitors to determine the firm's financial worth.
Arcturus Therapeutics Holdings is rated below average in price to book category among its peers. It is rated second in return on asset category among its peers . Return On Assets is likely to drop to -0.07 in 2024. Comparative valuation analysis is a catch-all technique that is used if you cannot value Arcturus Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Arcturus Return On Asset vs. Price To Book

Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.

Arcturus Therapeutics

P/B

 = 

MV Per Share

BV Per Share

 = 
1.75 X
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.
Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.

Arcturus Therapeutics

Return On Asset

 = 

Net Income

Total Assets

 = 
-0.12
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.

Arcturus Return On Asset Comparison

Arcturus Therapeutics is currently under evaluation in return on asset category among its peers.

Arcturus Therapeutics Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Arcturus Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Arcturus Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Arcturus Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Arcturus Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Operating Income-78.2 M-74.3 M
Income Before Tax-27.9 M-29.3 M
Total Other Income Expense Net50.3 M52.8 M
Net Loss-29.7 M-31.2 M
Income Tax Expense1.8 M1.9 M
Net Income From Continuing Ops99.3 M104.3 M
Net Income Applicable To Common Shares8.4 M8.8 M
Net Interest Income10.7 M11.3 M
Interest Income12.3 M12.9 M
Non Operating Income Net Other-739.8 K-776.8 K
Change To Netincome41.6 M43.7 M
Net Loss(1.12)(1.17)
Income Quality 0.61  0.70 
Net Income Per E B T 1.07  1.09 

Arcturus Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Arcturus Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Arcturus Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Arcturus Therapeutics' important profitability drivers and their relationship over time.

Use Arcturus Therapeutics in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Arcturus Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Arcturus Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Arcturus Therapeutics Pair Trading

Arcturus Therapeutics Holdings Pair Trading Analysis

The ability to find closely correlated positions to Arcturus Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Arcturus Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Arcturus Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Arcturus Therapeutics Holdings to buy it.
The correlation of Arcturus Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Arcturus Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Arcturus Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Arcturus Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Arcturus Therapeutics position

In addition to having Arcturus Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Alternative Currency ETFs Thematic Idea Now

Alternative Currency ETFs
Alternative Currency ETFs Theme
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Alternative Currency ETFs theme has 48 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Alternative Currency ETFs Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for Arcturus Stock Analysis

When running Arcturus Therapeutics' price analysis, check to measure Arcturus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcturus Therapeutics is operating at the current time. Most of Arcturus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Arcturus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcturus Therapeutics' price. Additionally, you may evaluate how the addition of Arcturus Therapeutics to your portfolios can decrease your overall portfolio volatility.